Phase IV

Mallinckrodt Plc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Mallinckrodt Presents Data Evaluating INOmax, for Inhalation in Neonates with Pulmonary Hypertension at PAS 2021 Virtual Meeting

Lead Product(s): Nitric Oxide

Therapeutic Area: Cardiology/Vascular Diseases Product Name: INOmax

Highest Development Status: Phase IV Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 30, 2021

Details:

A total of 50 (90.9 percent) PT and 75 (88.2 percent) TNT neonates achieved a ≥25 percent decrease in OI/SOI during treatment with INOmax.

Daiichi Sankyo Co Ltd

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

JAPAN Japan

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

New Two-Years Follow-up Data from ETNA-AF-Europe Reaffirms Benefit of LIXIANA® (Edoxaban) in People with Atrial Fibrillation

Lead Product(s): Edoxaban

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Lixiana

Highest Development Status: Phase IV Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 26, 2021

Details:

Large routine clinical practice study, ETNA-AF-Europe, demonstrates continued benefits of edoxaban across age groups and supports treatment in elderly patient populations, in line with those observed in ETNA-AF after one year and in ENGAGE AF-TIMI 48.